Sol-Gel Technologies Ltd.'s SEC filings document the disclosure record of a foreign private issuer developing and partnering dermatology drug products. Form 6-K reports include operating and financial results, unaudited condensed financial statements, clinical and regulatory updates for SGT-610, SGT-210 and EPSOLAY, and material-event disclosures incorporated by reference into the company's Form S-8 and Form F-3 registration statements.
The filings also cover shareholder meeting materials, auditor appointments, board elections, interim executive leadership approvals under Israeli corporate governance requirements, and capital-structure matters involving the company's ordinary shares. These documents frame Sol-Gel's public-company reporting around dermatology pipeline development, approved topical products, licensing arrangements, governance actions, and financing capacity.
Sol-Gel Technologies Ltd. (SLGL) ordinary shares are the subject of an amended ownership statement in which Opaleye Management Inc. and its controlling person, James Silverman, may be deemed beneficial owners of 540,000 shares, or 16.49% of the class. Opaleye, L.P. directly holds 525,000 shares, or 16.04%; a separately managed account advised by Opaleye Management holds 15,000 shares.
Opaleye, L.P. reported shared voting and dispositive power over its 525,000 shares. Opaleye Management and Silverman reported those powers over the 540,000-share aggregate. The percentages are based on 3,273,999 ordinary shares outstanding as of October 6, 2026.
Sol-Gel Technologies Ltd. is the issuer for which Trails Edge Biotechnology Master Fund, LP reports direct ownership of 166,473 ordinary shares, equal to 5.1%, as of October 20, 2026. Trails Edge Capital Partners, LP, the fund’s investment manager, and Ortav Yehudai, the manager’s chief investment officer, may each be deemed beneficial owners of the same shares.
The ownership percentage is based on 3,273,999 shares issued and outstanding as of October 6, 2026.
Sol-Gel Technologies Ltd. seeks shareholder approval on six proposals at its November 17, 2026 annual meeting. They include appointing Kesselman & Kesselman as auditor for 2026 through the next annual meeting; re-electing Moshe Arkin, Itai Arkin, Hanna Lerman and Sharon Kochan for one-year terms; and re-electing external directors Ran Gottfried and Yuval Yanai for three-year terms after their current terms expire. The Board recommends voting “FOR” all proposals.
Shareholders are also asked to appoint Moshe Arkin, the interim CEO, Executive Chairman and controlling shareholder, as CEO for three years effective January 1, 2027. He beneficially holds approximately 56% of the company’s outstanding shares and would remain Executive Chairman. Another proposal would allow a company name containing “Sol-Gel,” subject to approval by Israel’s Registrar of Companies and to take effect within 12 months of the meeting; proposed names include Sol-Gel Therapeutics Ltd. and Sol-Gel Dermatology Ltd.
The Board proposes increasing registered share capital from 5,000,000 to 8,000,000 ordinary shares, with par value NIS 1.00 per share. The change would not itself authorize issuance; future issuances require approvals under Israeli law. Sol-Gel reported 3,273,999 ordinary shares issued and outstanding as of October 6, 2026. Shareholders of record October 7, 2026 may vote.
Sol-Gel Technologies Ltd. announced it will host a KOL Investor Event for SGT-610 (patidegib gel, 2%) on October 14, 2026, in New York. Julie Breneiser, PA-C (Gorlin Syndrome Alliance), Ervin Epstein Jr., MD (Alta Bates Summit Medical Center), Kavita Sarin, MD, PhD (Stanford Cancer Institute), and Elizabeth M. Billingsley, MD, FAAD, FACMS, FASDS (Penn State College of Medicine) will discuss Gorlin Syndrome disease burden and the lack of effective therapies.
SGT-610 is Sol-Gel’s lead investigational candidate, a Phase 3, orphan- and breakthrough-designated topical hedgehog inhibitor being developed for the prevention of new basal cell carcinoma lesions in patients with Gorlin Syndrome.
Sol-Gel Technologies Ltd. (SLGL) reported that the last patient has completed the final scheduled visit in its pivotal Phase 3 clinical trial (SGT-610-01) of SGT-610 (patidegib gel, 2%) for prevention of basal cell carcinoma lesions in adults with Gorlin syndrome. This last patient last visit milestone completes the treatment and follow-up phase, after which the company will conduct database lock and statistical analysis, with top-line results expected in late November 2026. The randomized, double-blind, vehicle-controlled study enrolled 113 patients, of whom 102 completed 12 months of twice-daily treatment with either SGT-610 or vehicle, with a primary endpoint of the number of new facial BCCs at month 12 and secondary endpoints including new surgically eligible BCCs.
The company highlights SGT-610 as its lead investigational candidate, described as an orphan- and breakthrough-designated topical hedgehog inhibitor being developed for Gorlin syndrome and potentially high-frequency BCC, alongside its pipeline candidate SGT-210 and its two FDA-approved dermatology products TWYNEO and EPSOLAY.
Sol-Gel Technologies Ltd. (SLGL) reports that Opaleye Management Inc., a ten percent owner, indirectly purchased 3,124 ordinary shares in open-market transactions on September 10–11, 2026 through Opaleye, L.P. A separately managed account for which Opaleye Management acts as portfolio manager held 15,000 ordinary shares as of September 10, 2026. Opaleye Management may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.
Sol-Gel Technologies Ltd. (SLGL) reports that Opaleye Management Inc., a ten percent owner, indirectly purchased additional ordinary shares over several days in September 2026. Through Opaleye, L.P., it bought a total of 9,976 ordinary shares between September 4 and September 9, 2026 at prices generally around $68–$70 per share, including weighted-average purchases with disclosed price ranges. Opaleye Management Inc. reports these positions as indirectly held and disclaims beneficial ownership beyond its pecuniary interest, and no Rule 10b5-1 trading plan is reported.
Sol-Gel Technologies Ltd. (SLGL) had insider activity reported by Opaleye Management Inc., a more-than-10% owner. On September 1–2, 2026, entities it manages purchased 1,683 ordinary shares of Sol-Gel in open-market or private transactions at prices around $68.94–$69.52 per share, held indirectly through a fund and a managed account. A managed account associated with Opaleye Management Inc. held 15,000 ordinary shares after these transactions. No Rule 10b5-1 trading plan is reported, and Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest.
Sol-Gel Technologies Ltd. (SLGL) reports that large shareholder Opaleye Management Inc. filed a Form 4 showing open-market purchases of 40,330 ordinary shares on August 28 and 31, 2026. The shares were acquired indirectly through Opaleye, L.P. and a separately managed account, with 15,000 shares reported as held in the managed account. Certain trades used weighted average prices within disclosed ranges, and Opaleye Management Inc. disclaims beneficial ownership except to the extent of its pecuniary interest.
Sol-Gel Technologies Ltd. (SLGL) reported a sharp year-over-year decline in revenue and a swing to loss for the quarter ended June 30, 2026, while emphasizing progress in its late-stage dermatology pipeline. Second-quarter 2026 revenue was $0.6 million, down from $17.3 million a year earlier, mainly because the 2025 period included $16.7 million from a one-time sale of IP under the Mayne agreement.
Research and development expenses fell to $3.7 million from $4.6 million, and general and administrative expenses declined to $1.0 million from $1.4 million. The company posted a net loss of $3.7 million (loss of $1.13 per share), versus net income of $11.6 million ($4.17 per share) in the prior-year quarter. As of June 30, 2026, Sol-Gel held $18.0 million in cash, cash equivalents and deposits and $31.3 million in marketable securities, totaling $49.3 million, and expects these resources to fund operations into the first quarter of 2028.
The company highlighted continued advancement of its pivotal Phase 3 trial of SGT-610 (patidegib gel, 2%) in Gorlin syndrome, with last patient last visit expected in September 2026 and top-line data anticipated in late November 2026. Additional studies are underway in high-frequency basal cell carcinoma and as a neo-adjuvant treatment in BCC surgery, and Sol-Gel filed a provisional patent for an intra-cystic injectable hedgehog inhibitor for odontogenic keratocysts.